Trial AGO-OVAR2.29

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

AGO-OVAR2.29

Full title

Atezolizumab in Kombination mit Bevacizumab und Chemotherapie versus Bevacizumab und Chemotherapie beim rezidivierendem Ovarialkarzinom – eine randomisierte Phase III Studie

EudraCT number

2017-000202-37

NCT number

NCT03353831

Responsible organization

Frauenklinik GH, Telefon: 089440076800

Indications

Classification	Code	Description
-		Gynecological tumor
ICD-10-GM	C56	Bösartige Neubildung des Ovars

Trial design

Trial type

Interventional

Blinding type

Double blinded

Phase

III

Status

Recruitment active

Votes

Institutional review board - vote

Unknown

Initiiation & lock

Date of lock (planned / actual)

2024-12-01 / Unknown

Participants

	Function	Prename	Surname	Organization
	Principal Investigator	Alexander	Burges	Keine Organisationseinheit angegeben